This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Alemtuzumab and Pentostatin In T-cell Neoplasms

This study has been terminated.
(Slow accrual.)
Sponsor:
Collaborators:
Astex Pharmaceuticals
Bayer
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00453193
First received: March 26, 2007
Last updated: August 1, 2012
Last verified: August 2012
Results First Received: March 1, 2011  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Lymphoma
Leukemia
Interventions: Drug: Pentostatin
Drug: Alemtuzumab

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment Period: 8/241/2004 to 5/12/2009. All patients registered at The University of Texas M.D. Anderson Cancer Center.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Of the 26 enrolled, only 24 patients were included in this study.

Reporting Groups
  Description
Alemtuzumab + Pentostatin Alemtuzumab 30 mg intravenous (IV) three times weekly; Pentostatin 4 mg/m^2 IV weekly for 4 weeks then every 2 weeks

Participant Flow:   Overall Study
    Alemtuzumab + Pentostatin
STARTED   24 
COMPLETED   24 
NOT COMPLETED   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Alemtuzumab + Pentostatin Alemtuzumab 30 mg intravenous (IV) three times weekly; Pentostatin 4 mg/m^2 IV weekly for 4 weeks then every 2 weeks

Baseline Measures
   Alemtuzumab + Pentostatin 
Overall Participants Analyzed 
[Units: Participants]
 24 
Age 
[Units: Years]
Median (Full Range)
 57 
 (21 to 79) 
Gender 
[Units: Participants]
 
Female   10 
Male   14 
Region of Enrollment 
[Units: Participants]
 
United States   24 


  Outcome Measures

1.  Primary:   Number of Participants With Objective Response   [ Time Frame: After a maximum of 6 months of therapy maintained for one month. ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Farhad Ravandi-Kashani MD/Associate Professor
Organization: The University of Texas M D Anderson Cancer Center
phone: 713-745-0394
e-mail: eharriso@mdanderson.org



Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00453193     History of Changes
Other Study ID Numbers: 2004-0408
Study First Received: March 26, 2007
Results First Received: March 1, 2011
Last Updated: August 1, 2012